Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection

Alessandra Viganò, Len Dally, Dorella Bricalli, Natascia Sala, Maria Pirillo, Marina Saresella, Daria Trabattoni, Stefano Vella, Mario Clerici, Nicola Principi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Clinical, virologic, and immunologic outcomes were analyzed in children with vertically transmitted human immunodeficiency virus (HIV) infection (n = 95) and clinical symptoms and evidence of immunosuppression to establish the efficacy of 18 months' treatment with stavudine, lamivudine, and indinavir. Children were naive for treatment with protease inhibitors and lamivudine and had minimal exposure to stavudine. At 1, 6, 12, and 18 months, the proportions of patients with HIV-RNA + count and percent increased significantly in both CDC immunologic class groups, but to a greater extent in the class 3 group. In the 12- to 18-month period, there were no significant changes within the groups. In both groups there was a steady increase in the proportion and number of children with positive skin test responses. Children in class 2 were more likely to have a positive delayed-type hypersensitivity response and a greater number of positive responses. Lymphocyte proliferative response to recall antigens improved significantly in all patients. The rate of increase in positive test results was faster in children in class 2 than in those in class 3. Only minor clinical events occurred during 18 months of therapy. Potent antiretroviral therapy achieves a sustained benefit in HIV-infected children, but immune reconstitution is more likely achieved in children with less advanced disease.

Original languageEnglish
Pages (from-to)675-682
Number of pages8
JournalJournal of Pediatrics
Volume135
Issue number6
Publication statusPublished - 1999

Fingerprint

Indinavir
Stavudine
Lamivudine
Virus Diseases
HIV
Delayed Hypersensitivity
Therapeutics
Centers for Disease Control and Prevention (U.S.)
Skin Tests
Protease Inhibitors
Immunosuppression
Lymphocytes
RNA
Antigens

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. / Viganò, Alessandra; Dally, Len; Bricalli, Dorella; Sala, Natascia; Pirillo, Maria; Saresella, Marina; Trabattoni, Daria; Vella, Stefano; Clerici, Mario; Principi, Nicola.

In: Journal of Pediatrics, Vol. 135, No. 6, 1999, p. 675-682.

Research output: Contribution to journalArticle

Viganò, A, Dally, L, Bricalli, D, Sala, N, Pirillo, M, Saresella, M, Trabattoni, D, Vella, S, Clerici, M & Principi, N 1999, 'Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection', Journal of Pediatrics, vol. 135, no. 6, pp. 675-682.
Viganò, Alessandra ; Dally, Len ; Bricalli, Dorella ; Sala, Natascia ; Pirillo, Maria ; Saresella, Marina ; Trabattoni, Daria ; Vella, Stefano ; Clerici, Mario ; Principi, Nicola. / Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. In: Journal of Pediatrics. 1999 ; Vol. 135, No. 6. pp. 675-682.
@article{af00d3a6dd974784b04e71e5bc4512b1,
title = "Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection",
abstract = "Clinical, virologic, and immunologic outcomes were analyzed in children with vertically transmitted human immunodeficiency virus (HIV) infection (n = 95) and clinical symptoms and evidence of immunosuppression to establish the efficacy of 18 months' treatment with stavudine, lamivudine, and indinavir. Children were naive for treatment with protease inhibitors and lamivudine and had minimal exposure to stavudine. At 1, 6, 12, and 18 months, the proportions of patients with HIV-RNA + count and percent increased significantly in both CDC immunologic class groups, but to a greater extent in the class 3 group. In the 12- to 18-month period, there were no significant changes within the groups. In both groups there was a steady increase in the proportion and number of children with positive skin test responses. Children in class 2 were more likely to have a positive delayed-type hypersensitivity response and a greater number of positive responses. Lymphocyte proliferative response to recall antigens improved significantly in all patients. The rate of increase in positive test results was faster in children in class 2 than in those in class 3. Only minor clinical events occurred during 18 months of therapy. Potent antiretroviral therapy achieves a sustained benefit in HIV-infected children, but immune reconstitution is more likely achieved in children with less advanced disease.",
author = "Alessandra Vigan{\`o} and Len Dally and Dorella Bricalli and Natascia Sala and Maria Pirillo and Marina Saresella and Daria Trabattoni and Stefano Vella and Mario Clerici and Nicola Principi",
year = "1999",
language = "English",
volume = "135",
pages = "675--682",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection

AU - Viganò, Alessandra

AU - Dally, Len

AU - Bricalli, Dorella

AU - Sala, Natascia

AU - Pirillo, Maria

AU - Saresella, Marina

AU - Trabattoni, Daria

AU - Vella, Stefano

AU - Clerici, Mario

AU - Principi, Nicola

PY - 1999

Y1 - 1999

N2 - Clinical, virologic, and immunologic outcomes were analyzed in children with vertically transmitted human immunodeficiency virus (HIV) infection (n = 95) and clinical symptoms and evidence of immunosuppression to establish the efficacy of 18 months' treatment with stavudine, lamivudine, and indinavir. Children were naive for treatment with protease inhibitors and lamivudine and had minimal exposure to stavudine. At 1, 6, 12, and 18 months, the proportions of patients with HIV-RNA + count and percent increased significantly in both CDC immunologic class groups, but to a greater extent in the class 3 group. In the 12- to 18-month period, there were no significant changes within the groups. In both groups there was a steady increase in the proportion and number of children with positive skin test responses. Children in class 2 were more likely to have a positive delayed-type hypersensitivity response and a greater number of positive responses. Lymphocyte proliferative response to recall antigens improved significantly in all patients. The rate of increase in positive test results was faster in children in class 2 than in those in class 3. Only minor clinical events occurred during 18 months of therapy. Potent antiretroviral therapy achieves a sustained benefit in HIV-infected children, but immune reconstitution is more likely achieved in children with less advanced disease.

AB - Clinical, virologic, and immunologic outcomes were analyzed in children with vertically transmitted human immunodeficiency virus (HIV) infection (n = 95) and clinical symptoms and evidence of immunosuppression to establish the efficacy of 18 months' treatment with stavudine, lamivudine, and indinavir. Children were naive for treatment with protease inhibitors and lamivudine and had minimal exposure to stavudine. At 1, 6, 12, and 18 months, the proportions of patients with HIV-RNA + count and percent increased significantly in both CDC immunologic class groups, but to a greater extent in the class 3 group. In the 12- to 18-month period, there were no significant changes within the groups. In both groups there was a steady increase in the proportion and number of children with positive skin test responses. Children in class 2 were more likely to have a positive delayed-type hypersensitivity response and a greater number of positive responses. Lymphocyte proliferative response to recall antigens improved significantly in all patients. The rate of increase in positive test results was faster in children in class 2 than in those in class 3. Only minor clinical events occurred during 18 months of therapy. Potent antiretroviral therapy achieves a sustained benefit in HIV-infected children, but immune reconstitution is more likely achieved in children with less advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=0033504610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033504610&partnerID=8YFLogxK

M3 - Article

VL - 135

SP - 675

EP - 682

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 6

ER -